Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• KRAS proto-oncogene mutations are prevalent in metastatic cancers, including pancreatic, lung, and colorectal types.
• KRAS mutations are associated with poor response to conventional cancer treatments, highlighting the need for targeted therapies.
• KRAS was historically considered 'undruggable' but has seen significant progress with approved drugs and ongoing development.

Purpose of the Study:

• To review the development of KRAS-targeted molecules.
• To emphasize diverse drug design strategies for KRAS inhibition.
• To assess pharmacological attributes and clinical potential of KRAS inhibitors.

Main Methods:

• Direct inhibition of KRAS mutants via small molecule binders.
• Inhibition of activated KRAS mutants using small molecule binders and cyclophilin A complexes.
• Targeted degradation of KRAS mutants employing Proteolysis Targeting Chimeras (PROTACs).

Main Results:

• Multiple drug design strategies are being investigated for KRAS-targeted therapy.
• Several KRAS inhibitors are in clinical development, with some already approved.
• The review assesses the efficacy and clinical benefits of various KRAS-targeting approaches.

Conclusions:

• KRAS is now a druggable target, moving beyond its 'undruggable' status.
• Diverse strategies are advancing the development of KRAS inhibitors for cancer treatment.
• Future research will focus on optimizing KRAS inhibitors for enhanced anticancer efficacy.